



Biotech Daily

Wednesday October 7, 2026

Daily news on ASX-listed biotechnology companies

- * ASX FLAT, BIOTECH DOWN: CYCLOPHARM UP 12%; LUMOS DOWN 9%
- * CSL US BONDS RAISE \$2.15b
- * TELIX STARTS US COMMERCIAL PIXCLARA BRAIN IMAGING
- * SYNTARA: 'SNT-4728 IMPROVES PARKINSON'S MOTOR SIGNS'
- * MICROBA GI NAVIGATOR GUT TEST AVAILABLE IN AUSTRALIA, UK
- * CYCLOPHARM: 'TECHNEGAS PREFERRED FOR LUNG IMAGING IN CHINA'
- * ENTROPY DOSES 1st 1-HOUR INFUSED TRP-8803 BINGE-EATING PATIENT
- * AROVELLA SHIPS 2nd ALA-101 BATCH FOR PHASE I TRIAL
- * RHYTHM MODELLING: 'COLOSTAT REDUCES COLONOSCOPY BY 36%'
- * ADHERIUM TRUDELL'S BARVEST \$700k LOAN
- * CYNATA \$1.7m FEDERAL RDTI; REPAYS LOAN
- * PYC: 'PYC-003 REDUCES URINARY PROTEIN LEVELS BY 46%'
- * RECCE SECTION 249N DIRECTORS, CONDITIONAL SPILL AGM
- * ANTEOTECH 11.7m BOARD OPTIONS, 2.3m M-D SHARES AGM
- * AJAVA TAKES 7% OF STARPHARMA
- * FIRSTCAPE INCREASES, DILUTED TO 10% OF PACIFIC EDGE
- * REGAL INCREASES, DILUTED TO 12% OF IDT
- * MAGELLAN TAKES 5.5% OF CHIMERIC
- * ADHERIS TO REPORT IN US DOLLARS TO DECEMBER 31
- * DR JOHN LE GALL REPLACES IMUGENE CMO DR JOHN BYON
- * VITRAFY M-D BRENT OWENS TO US, ON \$779k PA
- * NANOSONICS CORIS WINS GOLD GOOD DESIGN GONG

MARKET REPORT

The Australian stock market slipped 0.09 percent on Wednesday October 7, 2026, with the ASX200 down 8.0 points to 8,727.7 points. Thirteen of the Biotech Daily Top 40 were up, 18 fell, eight traded unchanged and one was untraded. The four Big Caps were mixed.

Cyclopharm was the best (see below), up 5.5 cents or 12.0 percent to 51.5 cents, with 380,825 shares traded. Aroa rose seven percent; Resonance was up 6.4 percent; Alcidion, Artrya and Syntara climbed five percent or more; Curvebeam was up 4.8 percent; Atomo and Telix rose more than two percent; CSL, Mesoblast, Nanosonics, Pro Medicus and Starpharma were up more than one percent; with Clinuvel up by 0.9 percent.

Lumos led the falls, down 1.0 cent or 9.1 percent to 10 cents, with 934,119 shares traded. Micro-X lost 5.6 percent; Amplia and Racura fell more than four percent; Clarity, Emvision, Immuteq and Nova Eye were down more than three percent; 4D Medical, Avita, Dimerix, EBR, Imricor and Saluda shed two percent or more; Actinogen, Orthocell and Polynovo were down more than one percent; with Cochlear, Neuren and Resmed down by less than one percent.

CSL

CSL says that it has raised \$US1.5 billion (\$A2.15 billion) through the issue of US corporate bonds.

In 2024, CSL said that it had raised \$US1.25 billion through the issue of US corporate bonds to four banks (BD: Mar 27, 2024).

Today, the company said that it would raise \$US500 million in notes at a fixed rate of 5.948 percent per annum for seven years, with \$US1,000 million in notes to be issued at 6.201 percent a year for 10 years.

Biotech Daily understands that JP Morgan, Hongkong and Shanghai Banking Corporation (HSBC), Morgan Stanley and Goldman Sachs are the arranging banks.

CSL said it would refinance existing debt and use the funds for general purposes.

The company said settlement was expected on October 14, 2026, subject to conditions.

CSL was up \$3.31 or 1.85 percent to \$181.99 with 1.5 million shares traded.

TELIX PHARMACEUTICALS

Telix says it has dosed the first US patients with its Pixclara floretyrosine F-18 brain cancer imaging agent, "marking the start of commercial availability".

In an email not released to the ASX, the company said Pixclara was administered to patients at the Indiana University Health Neuroscience Center in Indianapolis and the University Hospitals Cleveland Medical Center in Ohio, with finished unit doses supplied by its US manufacturing and distribution partner Pharmalogic Holdings.

Last month, Telix said the US Food and Drug Administration approved Pixclara positron emission tomography (PET) for imaging brain cancer gliomas (BD: Sep 14, 2026).

Today, Telix said Pixclara was the only FDA-approved radio-pharmaceutical imaging drug for glioma and was indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related change in adults and children; and in a phase III study for a potential expanded indication in the diagnosis of brain metastases.

Telix was up 46 cents or three percent to \$15.87 with 2.8 million shares traded.

SYNTARA

Syntara says further data shows SNT-4728 led to “a statistically significant difference in clinician-assessed motor signs” for Parkinson’s disease versus placebo ($p=0.021$).

In July, Syntara said preliminary analysis of its 41-patient, phase II study of SNT-4728 for isolated rapid eye movement (REM) sleep behavior disorders, associated with a high risk of progression to Parkinson’s and related diseases showed “a statistically significant reduction in brain inflammation unilaterally in the putamen ($p = 0.0145$)” (BD: Jul 6, 2026). Today, the company said the secondary clinical endpoint results of motor function from the completed clinical dataset at week-12 and week-24 was measured by the Movement Disorder Society-unified Parkinson’s disease rating scale part III (MDS-UPDRS), “a widely used multi-domain clinical outcome assessment”.

Syntara said participants treated with SNT-4728 showed “slightly improved motor function according to their MDS-UPDRS part III total score after the 12-week treatment period whereas participants receiving placebo showed a worsening in motor scores”.

The company said at week-24, after 12 weeks off treatment, the motor scores of participants who had been treated with SNT-4728 showed “further improvement whilst the motor scores of participants in the placebo group continued to deteriorate”.

Syntara said the “converging evidence of biological activity and improvement in motor function supports further clinical development of SNT-4728 as a potential disease-modifying therapy in prodromal and early Parkinson’s disease”.

The company said that no treatment-related serious adverse events were reported, and all adverse events previously reported in treatment arms were mild or moderate.

Syntara said “no marked changes over time were observed in other ... measures or in overall cognitive, quality-of-life and isolated ... questionnaire measures”.

The company said “given the exploratory nature of these assessments, the small study size and the relatively short 12-week treatment period, the study was not designed to detect changes across all clinical and participant-reported measures”.

Syntara said the results would be presented at the Congress of Parkinson’s Disease and Movement Disorders, to be held from October 4 to 8, 2026 in Soeul, South Korea.

Syntara managing-director Gary Phillips said the results supported SNT-4728’s “potential benefit for [isolated REM sleep behavioral disorder] and Parkinson’s patients”.

Syntara was up 0.1 cents or five percent to 2.1 cents with 3.8 million shares traded.

MICROBA LIFE SCIENCES

Microba says it has begun commercializing its GI Navigator clinical gut test for complex gastro-intestinal (GI) symptoms in Australia and the UK.

Microba said GI Navigator was available in Australia for \$549 a test and the UK for GBP399 (\$A758), paid by either the patient or the practitioner.

The company said the test included a single, at-home stool sample kit and a patient questionnaire, which was interpreted by its “proprietary Clinical Logic Engine to give practitioners clear interpretations and a personalized management plan”.

Microba said results were typically available within two-to-four weeks.

The company said the test was “designed to make microbiome testing practical for medical doctors, including [general practitioners] and gastro-enterologists, a significant next segment of the healthcare practitioner market for Microba’s tests”.

Microba said that more than 150 tests had been ordered by clinicians in the beta program ahead of launch” and more than 400 practitioners joined the GI Navigator waitlist, including more than 150 clinicians who had not previously ordered a test.

Microba was up 0.1 cents or two percent to five cents.

CYCLOPHARM

Cyclopharm says seven Chinese medical bodies have published a Consensus recommending Technegas as the preferred lung imaging agent in pulmonary embolism. Cyclopharm said the first of the Consensus' 10 recommendations was: "for ventilation imaging, [technetium-99m] Technegas was recommended as the preferred radio-pharmaceutical".

The company said the Consensus stated that the alternative agent, DTPA, or diethylene-triamine-penta-acetic acid, aerosol, was "to be used only if Technegas is unavailable".

Cyclopharm said the Consensus was published after a survey of nuclear medicine departments in multiple Chinese hospitals, which found that "practice varied in how lung scans were ordered and that interpretation depended heavily on specialist expertise".

The company said the publication's purpose was "to standardize how the scan is performed and reported across China".

In 2023, Cyclopharm said the US Food and Drug Administration approved Technegas for pulmonary embolism imaging (BD: Oct 2, 2023).

Today, the company said "Technegas' existing footprint extends to most provinces across China, where the nuclear medicine sector is expanding rapidly".

Cyclopharm managing-director James McBrayer said the recommendation was "a powerful statement from the physicians who manage these patients every day".

"When experts on both sides of the world look at the evidence separately and arrive at the same answer, it speaks to the clinical advantages of Technegas itself," he said.

"When the physicians who order the scan and the physicians who perform it agree, across four continents, that is no longer a regional preference," Mr McBrayer said.

Cyclopharm was up 5.5 cents or 12.0 percent to 51.5 cents.

ENTROPY NEURODYNAMICS (FORMERLY TRYPTAMINE THERAPEUTICS)

Entropy says it has dosed the first cohort two patient in its phase II study with a 60-minute, intra-venous infusion of TRP-8803 psilocin for binge-eating disorder.

Earlier this year, Entropy said it had approval to dose the second binge-eating cohort in its 12-patient, phase II trial of TRP-8803 intra-venous psilocin (BD: Jun 15, 2026).

Previously, the company said that psilocin was the active psychedelic metabolite of psilocybin found in 'magic mushrooms' (BD: Jul 1, 2024).

Today, Entropy said the patient received their first administration of TRP-8803 dosed intra-venously for 60-minutes and was safely discharged following all required post-treatment clinical assessments.

The company said the milestone marked the beginning of dosing in cohort two and followed "the encouraging results" from the first six patients treated with TRP-8803 at an infusion period of 140 minutes in cohort one.

Entropy said cohort two was "designed to evaluate whether TRP-8803 can reproduce the controlled psychedelic experience and encouraging clinical outcomes observed in cohort one within a substantially shorter treatment window".

The company said the second cohort reduced the infusion period and would "assess whether the shorter regimen can maintain the precise control over psychedelic onset, intensity and duration enabled by [intra-venous] administration".

Entropy chief executive officer Jason Carroll said completing the first 60-minute infusion was "an important milestone for TRP-8803 as treatment duration goes directly to one of the major challenges facing psychedelic medicine: whether these therapies can ultimately be delivered practically and at scale".

Entropy was unchanged at 3.8 cents with 2.5 million shares traded.

AROVELLA THERAPEUTICS

Arovella says it has produced and delivered a second batch of ALA-101 for use in its 46-patient, phase I trial of the CAR-INK T-cell therapy for blood cancers.

Earlier this year, Arovella said it had ethics approval to begin a first-in-human, phase I clinical trial of its ALA-101 chimeric antigen receptor (CAR) invariant natural killer (INK) T-cell therapy for patients with relapsed or refractory lymphomas and leukaemia at Melbourne's Alfred Hospital (BD: Jun 25, 2026).

Today, the company said the two batches released so far provided "sufficient material to complete dose escalation and begin dose expansion".

Arovella said a third batch was expected to be released by the end of December to provide sufficient material to complete the phase I trial.

The company said an additional phase I trial site had been opened at Melbourne's Epworth Hospital, with additional sites to be opened at Sydney's St Vincent's Hospital and Brisbane's Mater Hospital.

Arovella said that eligible patient screening and the addition of additional clinical hospital sites allowed it "to expand the trial quickly once the first patient was dosed this month".

Arovella chair David Williams said the company was "ready to go and will soon have enough product on the shelf to dose all 46 patients supported by five exceptional hospital sites as we move towards dosing expected in late October."

Arovella was up 0.1 cents or 2.1 percent to 4.8 cents.

RHYTHM BIOSCIENCES

Rhythm says an independent health economic study, paid by Rhythm, shows Colostat would lead to a 36 percent reduction in colonoscopies at public hospitals.

Last year, Rhythm said it had begun commercializing its Colostat colorectal cancer blood test in Australia; and earlier this year, said it had a first sale (BD: Dec 12, 2025).

Today, the company said the study was conducted by Sydney healthcare consultancy Value-Based Access Pty Ltd in a modelled group of about 83,000 people a year who see their general practitioner with possible bowel cancer symptoms, had not done a stool test and would be referred to a public hospital for a colonoscopy.

Rhythm said the study found that at an assumed price of \$250 for its Colostat test and \$3,163 for a colonoscopy, the use of its tests costing \$20.7 million avoided 29,427 colonoscopies costing \$93.1 million.

The company said about two-thirds of colonoscopies in Australia were conducted in private hospitals and that the study did not cover them.

Rhythm said that Colostat was not currently funded by Medicare and it intended to use the study with other relevant evidence and future studies to support an application seeking Medicare reimbursement.

The company said the results were "from an economic model, not from real-world use, and actual results may differ materially from the estimates presented".

Rhythm said the Colostat accuracy figures used in the study included that the test detected 90.3 percent of bowel cancers and gave a negative result for 54.3 percent of people who do not have cancer, figures which "come from a study that is still being reviewed by independent scientists".

The company said "no test is perfect [and] the model estimates that a small number of cancers would be missed by the blood test at first [and that] sending patients whose symptoms continue for a colonoscopy helps reduce this risk".

Rhythm fell 0.2 cents or 2.6 percent to 7.6 cents.

ADHERIUM

Adherium says it has taken a \$700,000 loan from the Trudell Medical-related Barvest Ventures, at 12 percent annual interest, repayable by September 30, 2027.

Last month, Adherium said it had taken a \$1.3 million, unsecured loan from London-Ontario-based major shareholder Trudell Medical, taking the total combined with its previous loans from Trudell to \$4.7 million (BD: Sep 16, 2026).

Today, the company said the additional loan from Barvest was unsecured and would be used to fund working capital requirements.

Adherium was untraded at 7.5 cents.

CYNATA THERAPEUTICS

Cynata says it has received \$1,694,183 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive program.

Cynata said the funding related to research and development expenditure for the year to June 30, 2026 and following the repayment of a loan secured against its expected incentive would receive net proceeds of \$1,066,884.

Earlier this year, the company said following two negative trial results all employees, including managing-director Dr Kilian Kelly, would be made redundant, with a reduced board to evaluate future options (BD: Jul 6, 2026).

At the time, Cynata said it had suspended or terminated outsourced activities "to the maximum extent possible, whilst preserving the company's intellectual property" and it had a \$600,000 loan from an unnamed lender secured against its expected Federal Government Research and Development Tax Incentive for the year to June 30, 2026.

Cynata was untraded at 1.1 cents.

PYC THERAPEUTICS

PYC says exploratory efficacy data shows a 46 percent increase in urinary PC1 protein levels in kidney disease patients treated with PYC-003 in its phase Ia/Ib trial.

Earlier this year, PYC said it dosed the first of up-to 48-patients in its phase Ib, open-label, multiple ascending dose study of PYC-003 for polycystic kidney disease; and later, said it had safety review committee approval to progress the study to the higher 2.4 milligram per kilogram dose (BD: May 7, 2026).

Today, the company said urinary PC1 protein levels were a marker of target engagement for PYC-003 in the kidney and were increased in seven patients in the phase Ia/Ib trial at day-14 compared to baseline.

PYC said additional data showed a reduced change in total kidney volume at three months after treatment with a single dose of PYC-003 compared to baseline in a pooled 18-patient cohort, with total kidney volume "an accepted surrogate marker of disease progression" for polycystic kidney disease.

The company said the data would be presented at the American Society of Nephrology conference to be held from October 22, 2026 in Denver Colorado.

PYC said the "encouraging exploratory efficacy data has been generated in a small number of patients over a short period of time and on endpoints that are variable by nature" and needed to be reproduced in repeat dose studies of PYC-003 in a larger number of patients treated over a longer period before drawing conclusions.

The company said it expected to present data from its ongoing phase Ib multiple dose study of PYC-003 and associated open-label extension study in 2027.

PYC fell 21 cents or 7.8 percent to \$2.47 with 7.9 million shares traded.

RECCE PHARMACEUTICALS

Recce says investors will vote on a potential second remuneration report strike, a conditional board spill and the election of four shareholder-nominated directors.

Last year, Recce said its annual general meeting voted 80.68 percent against the remuneration report and defeated the placement capacity (BD: Nov 5, 2025).

Under the Corporations Amendment (Improving Accountability on Director and Executive Remuneration) Act 2011 any company with a vote of 25 percent or more against the remuneration report in two successive annual meetings must vote on a board spill.

Today, the company said its annual meeting would vote on shareholder-nominated candidates Dr Paul MacLeman, Dr Jurgen Michaelis, Amos Meltzer and Diana Forsyth.

Last week, Recce said it had a Corporations Act (2001) section 249N notice from substantial shareholder Gavin William Brown calling for members to express opinions, form an advisory council and appoint the four directors (BD: Sep 30, 2026).

Today, the company recommended investors vote against the shareholder-nominated directors, with the meeting chair intending to cast all undirected proxies against votes.

Recce said shareholders would vote to re-elect directors Michele Dilizia and Alistair McKeough, approve the additional 10 percent placement capacity, ratify the prior issue of placement shares and adopt the employee incentive plan.

The meeting will be held online and at Automic, Level 5, 126 Phillip Street, Sydney on November 6, 2026 at 9am (AEST).

Recce was unchanged at 31.5 cents.

ANTEOTECH

Anteotech says its annual general meeting will vote to issue 11,666,000 options and 2,292,854 short-term incentive shares to its managing-director, chair and a director.

Anteotech said investors would vote to issue managing-director Merrill Gray 2,292,854 short-term incentive shares and 8,220,000 options as well as chair Glenda McLoughlin and director Dr Geoff Cumming 2,050,000 options and 1,396,000 options, respectively.

The company said the options were exercisable at the higher of 3.75 cents each and a 50 percent premium to the grant date closing price by the earlier of November 10, 2030 or six months after the relevant holder ceases to be a director of the company.

Anteotech said the options would vest in two equal tranches on the share price reaching 3.75 cents within 12 months and 5.0 cents within 24 months and were in addition to Ms Gray's \$487,860 yearly salary, Glenda McLoughlin's \$121,700 annual pay and Dr Cumming's \$83,000 fees.

The company said shareholders would vote to adopt the remuneration report, re-elect Dr Cumming as a director, ratify the prior issue of placement shares and options as well as approve the 10 percent placement facility.

The meeting will be held at Rydges South Bank, Rooftop South, Level 12, 9 Glenelg Street, Brisbane on November 10, 2026 at 10am (AEST).

Anteotech was up 0.1 cents or 6.7 percent to 1.6 cents with 1.7 million shares traded.

STARPHARMA HOLDINGS

Ajava Holdings Pty Ltd says it has increased its substantial shareholding in Starpharma from 25,799,212 shares (6.13%) to 34,828,784 shares (7.26%).

Perth's Ajava said that it bought shares between July 17 and October 1, 2026 at prices ranging from 57.0 cents a share to 95.8 cents a share.

Starpharma was up 1.5 cents or 1.8 percent to 83 cents with 2.15 million shares traded.

PACIFIC EDGE

Firstcape Group Ltd says it has increased and been diluted in Pacific Edge from 110,622,815 shares (10.818%) to 121,618,241 shares (9.793%).

The Wellington, New Zealand-based Firstcape said that with Harbour Asset Management, BNZ Investment Services and HB Were it bought 40,168,761 shares for \$8,622,700, or 21.5 cents a share, and sold 28,975,881 shares for \$7,222,046, or 24.9 cents a share. Earlier this year, Pacific Edge said its rights offer raised \$NZ10.7 million (\$A8.8 million) at 17 NZ cents a share (14 Australian cents), taking the total to \$NZ36.1 million (\$A29.8 million) (BD: Jun 3, 2026).

Pacific Edge was unchanged at 19 cents.

IDT AUSTRALIA

Regal Partners Funds Management Pty Ltd says it has increased and been diluted in IDT from 43,578,939 shares (12.99%) 51,448,296 shares (11.97%)

Sydney's Regal Partners said that it bought and sold shares between August 7, 2023 and October 2, 2026, with the single largest purchase 10,428,775 shares for \$938,590, or nine cents a share, and was diluted due to a share issue on October 5, 2026.

In a cleansing notice on Monday, IDT said it had issued 1,388,545 shares to its employees upon exercise of performance rights.

IDT fell 0.2 cents or five percent to 3.8 cents.

MAGELLAN FINANCIAL GROUP

Sydney's Magellan Financial Group Ltd says it has become a substantial shareholder in Chimeric with 8,048,943 shares, or 5.46 percent of the company.

Magellan said it bought shares between June 1 and September 30, 2026, with the single largest purchase 3,538,500 shares on September 30 for \$11,306, or 0.3 cents a share.

Earlier this year, the company said it would close its phase I/II CHM-2101 gastro-intestinal cancer trial, due to safety, and had implemented cost reductions (BD: Aug 19, 2026).

Last week, Chimeric said it delayed its annual report due to negotiations with creditors and a recapitalization, with the ASX suspending it under Listing Rule 17.5 (BD: Oct 1, 2026).

Chimeric was in a suspension and last traded at 0.3 cents.

ADHERIS HEALTH (FORMERLY MEDADIVSOR)

Adheris says it has changed its financial year end from June 30 to December 31 and has changed its functional currency from Australian dollars to US dollars.

Adheris said the change aligned its reporting period with its customers, being US-based pharmaceutical manufacturers, and their health program planning cycles.

The company said the Australian Securities and Investments Commission (ASIC) had been notified of the change, and it would report on a six-month transitional financial year from July 1, 2026 to December 31, 2026, with regular half-year and full-year reporting periods to follow, effective from January 1, 2027.

Adheris said since the sale of its Australia and New Zealand business most of its revenues and expenses were "now denominated in US dollars", with the reporting currency change effective from July 1, 2026.

Last year, the then Medadvisor said it sold its Australia and New Zealand business operations to Brisbane's Jonas Software Aus Pty Ltd (BD: Jul 2, 7, 2025).

Adheris was up 0.2 cents or 15.4 percent to 1.5 cents with 1.1 million shares traded.

IMUGENE

Imugene says it has appointed Dr John Le Gall as its chief medical officer, effective immediately, with Dr John Byon to step down “by mutual agreement”.

Imugene said Dr Le Gall was a physician-scientist and had been head of clinical development at Allogene Therapeutics and Instil Bi as well as a director of clinical development at Kite, a Gilead Company.

The company said Dr Le Gall held a Doctor of Medicine and a Master of Business Administration from New York’s Columbia University.

Imugene said Dr Byon would “continue to support the company as a consultant”.

The company said it had “restructured the chief medical officer role to match the company’s current scale of clinical activity and cost base” and did not expect any interruption to its azer-cel clinical program.

Imugene was unchanged at 4.1 cents with seven million shares traded.

VITRAFY LIFE SCIENCES

Vitrafy says it has increased managing-director Brent Owens’ salary to \$US535,000 (\$A767,100) a year, as well as \$US8,000 (\$A11,470) in health insurance.

Previously, Vitrafy said Mr Owens was paid \$389,765 per annum (BD: Oct 6, 2025).

Today, the company said that Mr Owens’ remuneration was “revised in line with his relocation to the US ... given Vitrafy’s significant market opportunities in the US”.

Vitrafy said Mr Owens would be paid \$US76,000 for one-off relocation costs including visa, immigration and tax advice, relocation airfares, shipment of goods, temporary accommodation and local set-up services, repayable if he resigned within 12 months without good reason or was terminated without cause.

The company said Mr Owens would be eligible to receive 150 percent of his fixed annual pay as a long-term incentive through the issue of performance rights, subject to vesting conditions and milestones.

Vitrafy fell one cent or 0.3 percent to \$3.50.

NANOSONICS

Nanosonics says it has won a Gold Award at the 2026 Australian Good Design Awards for its Coris endoscope cleaner in the ‘product design medical and scientific’ category.

Last year, Nanosonics said the US Food and Drug Administration approved its Coris device for cleaning biofilm in flexible endoscopes; and later, said the system was approved in Australia, the European Union and the UK (BD: Mar 20, Dec 11, 2025).

Today, in an email not released to the ASX, the company said the Coris system was “a new-to-world technology that automates the cleaning of flexible endoscopes before high-level disinfection”.

Nanosonics said flexible endoscopes were used for diagnostic and therapeutic purposes, however, their design made them “very difficult to clean”.

Nanosonics was up four cents or 1.4 percent to \$2.90 with 947,663 shares traded.